Tarsus Pharmaceuticals, Inc. TARS Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported unrealized gains (losses) on available-for-sale securities of -$679K in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities decreased by 622.3% year-over-year, from -$94K to -$679K.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s unrealized gains (losses) on available-for-sale securities has grown at a 65.2% compound annual growth rate (CAGR), from -$74K to $202K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric captures the change in the fair value of available-for-sale investment securities that has not yet been realized through a sale. It reflects market-driven fluctuations in the value of the company's liquid asset portfolio, providing insight into the volatility of non-operating financial holdings. Investors use this to distinguish between core operational performance and the impact of external financial market conditions on the company's balance sheet.